IL-17 Neutralizing Antibody Reverts the Functional and Structural Changes in Cigarette Smoke-Induced COPD Model

Chronic Obstructive Pulmonary Disease (COPD) is characterized by an abnormal inflammatory response in the airways and alveoli due to prolonged exposure to harmful particles or gases. Despite treatments like bronchodilators and corticosteroids, challenges remain due to the disease’s heterogeneity and medication side effects, such as pulmonary infections. Recent studies suggest that blocking IL-17 could reduce inflammation in lung injury models. This study evaluated the effects of an IL-17 neutralizing antibody in a cigarette smoke-induced COPD mouse model. Mice were exposed to cigarette smoke for 6 months, and treatment with the antibody was initiated in the 5th month. Three experimental groups were formed: control, COPD, and COPD + anti-IL-17. Results showed an increase in the mean linear intercept (Lm) in the COPD group, while treatment with the neutralizing antibody reversed the structural changes. Additionally, the expression of inflammatory cytokines and the RORγt gene was higher in the COPD group. The study concludes that IL-17 neutralizing antibody treatment can reverse functional and structural lung alterations in COPD.